JENA, Germany--(BUSINESS WIRE)--SIRS-Lab GmbH, a molecular diagnostics company based in Jena, Germany, and Pfizer Pharma GmbH, headquartered in Berlin, have announced a collaboration in the field of sepsis. The aim of this collaboration is to improve the outcome of patients with life-threatening infection, by using molecular diagnostic tests to achieve the earliest and most accurate targeting of anti-infective therapy.
The initial focus of the collaboration is on severe fungal blood-stream infections, with the goal to examine the impact of molecular test based diagnosis on the clinical outcome of patients with sepsis, as well as on the pharmacoeconomics of such interventions.
Barbara Staehelin, CEO of SIRS-Lab, said, “We are delighted to be working with Pfizer, one of the leaders in anti-infective therapy, and hope that this collaboration will help to improve the outcomes for patients with sepsis.”
Headquartered in Jena, Germany, with offices in Basel, Switzerland, SIRS-Lab is a molecular diagnostic company that develops and commercializes unique and innovative products to identify and monitor life-threatening infections such as sepsis, one of the major causes of death in hospitals. SIRS-Lab was founded in 2000 as a spin-off from the University of Jena, one of the world‘s leading sepsis centres. The company has developed a proprietary sample preparation technology LOOXSTER®, which is used within VYOO®, its CE-marked sepsis diagnostic test. With its upcoming product SIQNATURE®, the company also plans to allow gene expression monitoring of the body´s immune response to infection. Further information is at www.sirslab.com.
Sepsis occurs when microbes enter the bloodstream and trigger a severe inflammatory response by the patient´s body. This is often life-threatening, and the search for the appropriate antibiotic or antifungal treatment can be a race against time. Traditional diagnostics take several days to complete, and often miss the infection. Therefore patients are usually prescribed a mixture of anti-infective drugs to cover likely microbes. However, the increasing incidence of antibiotic resistance, and of fungal infections, means that many patients will not receive effective therapy. With molecular diagnostics, the microbe can be identified within hours, allowing rapid tailoring of the therapy. Sepsis affects more than 2 million people per year in Europe and North America, and is one of the leading causes of death in hospitals.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6522986&lang=en